Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04YWM
|
|||
| Former ID |
DCL000706
|
|||
| Drug Name |
Atacicept
|
|||
| Indication | Lymphoma [ICD-11: 2A80-2A86] | Phase 3 | [1], [2] | |
| Lupus [ICD-11: 4A40; ICD-9: 583.81] | Phase 2 | [3] | ||
| Multiple sclerosis [ICD-11: 8A40] | Phase 2 | [2] | ||
| Rheumatoid arthritis [ICD-11: FA20] | Phase 2 | [2] | ||
| Systemic lupus erythematosus [ICD-11: 4A40.0; ICD-9: 710] | Phase 2 | [4] | ||
| Company |
ZymoGenetics; Serono
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | A proliferation-inducing ligand (APRIL) | Target Info | Modulator | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Atacicept: a new B lymphocyte-targeted therapy for multiple sclerosis. Nervenarzt. 2009 Dec;80(12):1462-72. | |||
| REF 2 | New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21. | |||
| REF 3 | ClinicalTrials.gov (NCT01972568) Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus. U.S. National Institutes of Health. | |||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.